MEDROXYPROGESTERONE ACETATE INJECTABLE S

The Defense Logistics Agency awarded a delivery order under basic contract SPE2DX-25-D-9822 to DMS PHARMACEUTICAL GROUP INC (CAGE 1UNB0) for the procurement of two units of MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION, identified by NSN 6505015295618 and NDC 00009-7376-11, at a total contract value of $80.40. The award was issued on July 16, 2026, with delivery required no later than that date to the Electric Boat Corporation facility in North Stonington, Connecticut, under FOB destination terms, meaning the contractor assumes all freight costs and risks until receipt at the delivery point. The Government is responsible for inspection and acceptance upon arrival, and the product must be shipped by traceable means excluding parcel post, with all packaging and documentation marked using the assigned identification numbers. The awardee is certified as a small business, small disadvantaged business, and woman-owned small business, triggering applicable compliance and reporting obligations under federal socioeconomic programs. Payment will be processed through the Defense Finance and Accounting Service in Columbus, Ohio, using the provided accounting identifier BX: 97X4930 5CBX 001 2620 S33189 and payment code SL4701, with no additional invoicing system specified. The contract has no options, quantity variance, or extended performance period, and all terms are fixed and fully defined in the single-line item. While the solicitation number is SPE2D226F3037, no formal contract clauses under FAR, list of attachments under Section J, evaluation factors under Section M, or special requirements under Section H are documented in the provided materials. The ordering officer is Lisa Quinn, with Jayne Do serving as the local administrative contact, and no contracting officer’s representative is identified. The NAICS code 424210 classifies the procurement within pharmaceutical and botanical product wholesaling, and the absence of explicit MIL-STD or FDA documentation references implies reliance on established DoD supply chain standards and implied regulatory compliance for pharmaceuticals.